盐酸曲美他嗪治疗258例稳定型心绞痛临床疗效观察

Efficacy of the Trimetazidine on 258 cases with Stable Angina Pectoris

目的:探讨盐酸曲美他嗪治疗稳定型心绞痛(SAP)的临床疗效。方法:258例SAP患者随机分为对照组和观察组,每组129例。对照组给予常规治疗,观察组在常规治疗基础上加用盐酸曲美他嗪,治疗后比较两组临床疗效,心功能指数、6min步行距离及不良反应情况。结果:观察组住院时间为(12.52±5.48)d,显著低于对照组的(14.78±5.22)d(P<0.05);发作次数和时间显著低于对照组(P<0.05),6min钟步行距离和LEVF(%)显著高于对照组(P<0.05);两组总不良反应率差异无统计学意义(P>0.05)。结论:常规治疗基础上使用盐酸曲美他嗪能显著缓解SAP患者心绞痛症状,改善心肌供血,不良反应少,临床效果确切。

Objective. To investigate the efficacy of the Trimetazidine on Stable Angina Pectoris （SPA）. Methods= A total of 258 SAP patients were randomly divided into the control group and the obser- vation group, with 129 cases in each group. The control group was given conventional treatment, while the observation group was also given trimetazidine on the basis of conventional therapy. The clinical cura- tive effect, cardiac function index, 6 min walking distance and adverse reactions were observed and com- pared after treatment. Results= The hospitalization time of the observation group was（12.52±5.48）d, significant shorter than the （14.78±5.22）d of the control group （P〈0.05）, and the onset frequency and length of the observation group was lower than that of the control group （P〈0.05）. The 6min walking distance and LEVF （%） were all significantly higher than that in the control group （P〈0.05）. No signifi- cant difference in total adverse reaction rate were observed between the two groups （P〈0. 05）. Conclu- sions： Trimetazidine could significantly relieve the symptoms of SAP based on conventional treatment andimprove the myocardial blood supply. The clinical efficacy is obvious but adverse reactions are less.